

Phosphoglucomutase (PGM 1) Deficiency- Pipeline Insight, 2019

<https://marketpublishers.com/r/P112AA61611EN.html>

Date: August 2019

Pages: 60

Price: US\$ 1,250.00 (Single User License)

ID: P112AA61611EN

Abstracts

This report can be delivered to the clients within 24 Hours

"Phosphoglucomutase (PGM 1) Deficiency- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Phosphoglucomutase (PGM 1) Deficiency pipeline landscape is provided which includes the disease overview and Phosphoglucomutase (PGM 1) Deficiency treatment guidelines. The assessment part of the report embraces, in depth Phosphoglucomutase (PGM 1) Deficiency commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Phosphoglucomutase (PGM 1) Deficiency collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Phosphoglucomutase (PGM 1) Deficiency Understanding

Congenital disorders of glycosylation (CDGs) are a group of genetic metabolic diseases that are caused by defects in protein glycosylation. Phosphoglucomutase-1 deficiency (PGM1-CDG) is a special CDG that offers new insights into the highly complex relationship among protein glycosylation, other metabolic pathways, and organ system development, according to Sunnie Yan et al (2016). PGM1 Deficiency is caused by loss of function mutations in the PGM1 gene encoding an enzyme responsible for the interconversion of glucose-6-phosphate to glucose-1-phosphate. Glucose-1-phosphate can be utilized to supply UDP-galactose, a substrate that donates galactose subunits for glycoprotein synthesis. The phenotype of PGM1-CDG comprises a wide range of

clinical manifestations, including hypoglycemia, congenital malformations, early-onset dilated cardiomyopathy, growth retardation, hormonal deficiencies, hepatopathy, hemostatic anomalies, and myopathy.

Phosphoglucomutase (PGM 1) Deficiency Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Phosphoglucomutase (PGM 1) Deficiency targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Phosphoglucomutase (PGM 1) Deficiency pipeline report covers only one company. Some of the key players include Cerecor Inc. (CERC-801) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Phosphoglucomutase (PGM 1) Deficiency Analytical Perspective by Delve Insight

In-depth Phosphoglucomutase (PGM 1) Deficiency Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Phosphoglucomutase (PGM 1) Deficiency Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

The Phosphoglucomutase (PGM 1) Deficiency report provides an overview of therapeutic pipeline activity for Phosphoglucomutase (PGM 1) Deficiency across the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Phosphoglucomutase (PGM 1) Deficiency therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details

Detailed Phosphoglucomutase (PGM 1) Deficiency Research and Development progress and trial details, results wherever available, are also included in the pipeline study

Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Phosphoglucomutase (PGM 1) Deficiency

Reasons to Buy

Establish a comprehensive understanding of the current pipeline scenario across Phosphoglucomutase (PGM 1) Deficiency to formulate effective R&D strategies

Assess challenges and opportunities that influence Phosphoglucomutase (PGM 1) Deficiency R&D

Develop strategic initiatives by understanding the focus areas of leading companies.

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Get in detail information of each product with updated information on each project along with key milestones

Devise Phosphoglucomutase (PGM 1) Deficiencyin licensing and out licensing strategies by identifying prospective partners with progressing projects for Phosphoglucomutase (PGM 1) Deficiencyto enhance and expand business potential and scope

Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Contents

1. REPORT INTRODUCTION

2. PHOSPHOGLUCOMUTASE (PGM 1) DEFICIENCY

- 2.1. Phosphoglucomutase (PGM 1) Deficiency Disease Overview
- 2.2. Phosphoglucomutase (PGM 1) Deficiency History
- 2.3. Phosphoglucomutase (PGM 1) Deficiency Symptoms
- 2.4. Phosphoglucomutase (PGM 1) Deficiency Causes
- 2.5. Phosphoglucomutase (PGM 1) Deficiency Pathophysiology
- 2.6. Phosphoglucomutase (PGM 1) Deficiency Diagnosis
 - 2.6.1. Diagnostic Guidelines

3. PHOSPHOGLUCOMUTASE (PGM 1) DEFICIENCY CURRENT TREATMENT PATTERNS

- 3.1. Treatment Guidelines

4. PHOSPHOGLUCOMUTASE (PGM 1) DEFICIENCY- DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

- 4.1. In-depth Commercial Assessment
 - 4.1.1. Phosphoglucomutase (PGM 1) Deficiency companies collaborations, Licensing, Acquisition –Deal Value Trends
 - 4.1.1.1. Assessment Summary
 - 4.1.2. Phosphoglucomutase (PGM 1) Deficiency Collaboration Deals
 - 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
 - 4.1.2.2. Phosphoglucomutase (PGM 1) Deficiency Acquisition Analysis
- 4.2. Clinical Assessment of Pipeline Drugs
 - 4.2.1. Assessment by Phase of Development
 - 4.2.2. Assessment by Product Type (Mono / Combination)
 - 4.2.2.1. Assessment by Stage and Product Type
 - 4.2.3. Assessment by Route of Administration
 - 4.2.3.1. Assessment by Stage and Route of Administration
 - 4.2.4. Assessment by Molecule Type
 - 4.2.4.1. Assessment by Stage and Molecule Type
 - 4.2.5. Assessment by MOA
 - 4.2.5.1. Assessment by Stage and MOA

5. PHOSPHOGLUCOMUTASE (PGM 1) DEFICIENCY PIPELINE THERAPEUTICS

5.1. Late Stage Products (Phase-III)

5.1.1. Comparative Analysis

5.2. Mid Stage Products (Phase-II)

5.2.1. Comparative Analysis

5.3. Early Stage Products (Phase-I)

5.3.1. Comparative Analysis

5.4. Pre-clinical and Discovery Stage Products

5.4.1. Comparative Analysis

5.5. Inactive Products

6. PHOSPHOGLUCOMUTASE (PGM 1) DEFICIENCY-PRODUCTS ANALYSIS

6.1. Product Profiles

6.1.1. CERC-801- Cerecor Inc.

6.1.1.1. Product Description

6.1.1.1.1. Product Overview

6.1.1.1.2. Mechanism of Action

6.1.1.2. Research and Development

6.1.1.2.1. Clinical Studies

6.1.1.2.1.1. Detailed Study Description

6.1.1.2.1.2. Study Results

6.1.1.2.1.3. Clinical Trials: Tabular View

6.1.1.3. Product Development Activities

6.1.1.3.1. Tabulated Product Summary

6.1.1.3.1.1. General Description Table

To be continued in the report.....

7. RECENT TECHNOLOGIES

8. PHOSPHOGLUCOMUTASE (PGM 1) DEFICIENCY KEY COMPANIES

8.1. Cerecor Inc.

9. PHOSPHOGLUCOMUTASE (PGM 1) DEFICIENCY KEY PRODUCTS

9.1. CERC-801

10. DORMANT AND DISCONTINUED PRODUCTS

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. PHOSPHOGLUCOMUTASE (PGM 1) DEFICIENCY- UNMET NEEDS

12. PHOSPHOGLUCOMUTASE (PGM 1) DEFICIENCY- FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

14.1. Secondary Research

14.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

Table 1. Phosphoglucomutase (PGM 1) Deficiency Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Phosphoglucomutase (PGM 1) Deficiency Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products

List Of Figures

LIST OF FIGURES

- Figure 1. Disease Overview
- Figure 2. History
- Figure 3. Symptoms
- Figure 4. Causes
- Figure 5. Pathophysiology
- Figure 6. Diagnostic Guidelines
- Figure 7. Treatment Guidelines
- Figure 8. Phosphoglucomutase (PGM 1) Deficiency companies collaborations, Licensing, Acquisition –Deal Value Trends
- Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
- Figure 10. Phosphoglucomutase (PGM 1) Deficiency Acquisition Analysis
- Figure 11. Assessment by Phase of Development
- Figure 12. Assessment by Product Type (Mono / Combination)
- Figure 13. Assessment by Stage and Product Type
- Figure 14. Assessment by Route of Administration
- Figure 15. Assessment by Stage and Route of Administration
- Figure 16. Assessment by Molecule Type
- Figure 17. Assessment by Stage and Molecule Type
- Figure 18. Assessment by MOA
- Figure 19. Assessment by Stage and MOA
- Figure 20. Late Stage Products (Phase-III)
- Figure 21. Mid Stage Products (Phase-II)
- Figure 22. Early Stage Products (Phase-I)
- Figure 23. Pre-clinical and Discovery Stage Products
- Figure 24. Inactive Products
- Figure 25. Dormant Products
- Figure 26. Discontinued Products
- Figure 27. Unmet Needs

KEY COMPANIES

Cerecor

I would like to order

Product name: Phosphoglucomutase (PGM 1) Deficiency- Pipeline Insight, 2019

Product link: <https://marketpublishers.com/r/P112AA61611EN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P112AA61611EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970